ABL1 (Y245F/Y412F)
Sign in to save this workspaceABL1 · Variant type: compound · HGVS: p.Y245F;p.Y412F
Components
p.Y245Fp.Y412F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Vandetanib | 94.2% | 5.8% | 95.74 |
| 2 | Tivozanib | 94.1% | 5.9% | 92.42 |
| 3 | Ripretinib | 92.2% | 7.8% | 92.95 |
| 4 | Selpercatinib | 85.8% | 14.2% | 96.72 |
| 5 | Sunitinib | 84.6% | 15.4% | 91.73 |
| 6 | Pacritinib | 83.8% | 16.2% | 88.64 |
| 7 | Fedratinib | 81.9% | 18.1% | 96.21 |
| 8 | Erdafitinib | 80.5% | 19.5% | 95.71 |
| 9 | Canertinib | 80.5% | 19.5% | 96.49 |
| 10 | Repotrectinib | 79.5% | 20.5% | 84.21 |
| 11 | Sorafenib | 66.7% | 33.3% | 96.72 |
| 12 | Apatinib | 60.1% | 39.9% | 97.73 |
| 13 | Erlotinib | 55.7% | 44.3% | 99.75 |
| 14 | Entrectinib | 53.1% | 46.9% | 93.69 |
| 15 | Neratinib | 52.7% | 47.3% | 93.18 |
| 16 | Asciminib | 51.6% | 48.4% | 100.00 |
| 17 | Pralsetinib | 51.3% | 48.7% | 93.43 |
| 18 | Infigratinib | 50.1% | 49.9% | 98.24 |
| 19 | Umbralisib | 47.5% | 52.5% | 98.74 |
| 20 | Avapritinib | 45.9% | 54.1% | 97.73 |
| 21 | Gilteritinib | 40.1% | 59.9% | 88.97 |
| 22 | Upadacitinib | 38.6% | 61.4% | 97.98 |
| 23 | Defactinib | 36.9% | 63.1% | 92.68 |
| 24 | Alpelisib | 36.3% | 63.7% | 97.22 |
| 25 | Deucravacitinib | 29.0% | 71.0% | 98.99 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Vandetanib | 94.2% | 95.7% | -1.5% |
| Tivozanib | 94.1% | 95.8% | -1.7% |
| Ripretinib | 92.2% | 82.9% | +9.3% |
| Selpercatinib | 85.8% | — | — |
| Sunitinib | 84.6% | — | — |
| Pacritinib | 83.8% | 92.0% | -8.3% |
| Fedratinib | 81.9% | 82.7% | -0.8% |
| Erdafitinib | 80.5% | 90.9% | -10.4% |
| Canertinib | 80.5% | 91.6% | -11.1% |
| Repotrectinib | 79.5% | 93.6% | -14.0% |
| Sorafenib | 66.7% | — | — |
| Apatinib | 60.1% | — | — |
| Erlotinib | 55.7% | — | — |
| Entrectinib | 53.1% | — | — |
| Neratinib | 52.7% | — | — |
| Asciminib | 51.6% | — | — |
| Pralsetinib | 51.3% | — | — |
| Infigratinib | 50.1% | — | — |
| Umbralisib | 47.5% | — | — |
| Avapritinib | 45.9% | — | — |
| Gilteritinib | 40.1% | — | — |
| Upadacitinib | 38.6% | — | — |
| Defactinib | 36.9% | — | — |
| Alpelisib | 36.3% | — | — |
| Deucravacitinib | 29.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 19.0ms